Limited real-world data exist on the effectiveness and safety of abiraterone acetate plus prednisone (abiraterone hereafter) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) naive to chemotherapy. Most of the few available studies had a retrospective design and included a small number of patients. In the interim analysis of the ABItude study, abiraterone showed good clinical effectiveness and safety profile in the chemotherapy-naive setting over a median follow-up of 18 months.
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study / Procopio, G; Chiuri, V E; Giordano, M; Alitto, A R; Maisano, R; Bordonaro, R; Cinieri, S; Rossetti, S; De Placido, S; Airoldi, M; Galli, L; Gasparro, D; Ludovico, G M; Guglielmini, P F; Carella, C; Nova, P; Aglietta, M; Schips, L; Beccaglia, P; Sciarra, A; Livi, L; Santini, D. - In: ESMO OPEN. - ISSN 2059-7029. - 7:2(2022), p. 100431. [10.1016/j.esmoop.2022.100431]
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study
Rossetti, S;De Placido, S;Aglietta, M;
2022
Abstract
Limited real-world data exist on the effectiveness and safety of abiraterone acetate plus prednisone (abiraterone hereafter) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) naive to chemotherapy. Most of the few available studies had a retrospective design and included a small number of patients. In the interim analysis of the ABItude study, abiraterone showed good clinical effectiveness and safety profile in the chemotherapy-naive setting over a median follow-up of 18 months.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
